

Investigating the effect of bintrafusp alfa, a bifunctional fusion protein designed for colocalized, simultaneous inhibition of the TGF- β and PD-L1 pathways, in multiple cancer types.

Bintrafusp alfa is under clinical investigation and has not been proven to be safe and effective. There is no guarantee that bintrafusp alfa will be approved in the sought-after indication by any health authority worldwide.

INTR@PID[™] BTC 047¹

Active, Not Recruiting



LOCALLY ADVANCED/METASTATIC
BTC



PHASE
2



MONOTHERAPY

INTR@PID BTC 047 (NCT03833661) is a phase 2, single-arm study evaluating bintrafusp alfa in the second-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC) that has failed or is intolerant of first-line platinum-containing chemotherapy.

Study design | Global



Key inclusion criteria[†]

- Participants must have histologically or cytologically confirmed locally advanced or metastatic BTC and an ECOG PS of 0 or 1. Participants must have not responded to or be intolerant of first-line platinum-containing chemotherapy;[‡] only 1 prior line of treatment is allowed


Key exclusion criteria[†]

- Participants must not have ampullary cancer, interstitial lung disease or its history, or received prior immunotherapy or therapy with immune checkpoint inhibitors

[†]Until confirmed disease progression, death, unacceptable toxicity, or study withdrawal. [‡]For a full list of inclusion and exclusion criteria, please visit www.clinicaltrials.gov. [†]First-line platinum-containing chemotherapy must have been administered for locally advanced or metastatic disease.

2L, second-line; BTC, biliary tract cancer; DOR, duration of response; DRR, durable response rate; ECOG PS, Eastern Cooperative Oncology Group performance status; IV, intravenous; OR, objective response; OS, overall survival; PD-L1, programmed death ligand 1; PFS, progression-free survival; Q2W, every 2 weeks; TGF- β , transforming growth factor β .

Reference: 1. ClinicalTrials.gov. M7824 monotherapy in locally advanced or metastatic second line (2L) biliary tract cancer (cholangiocarcinoma and gallbladder cancer). Accessed March 11, 2021. <https://clinicaltrials.gov/ct2/show/NCT03833661>.



For more information, visit
www.intrapidclinicaltrials.com
www.clinicaltrials.gov